Trenton Schmale, DO
Sports Medicine · Sheridan, INNPI 1851827935
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 39.4% of the total.
Across 212 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$293
- Novo Nordisk$226
- Lilly USA, LLC$217
- GSK$175
- Dexcom, Inc.$130
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,745100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 80 | $1,474 |
| AstraZeneca | 17 | $293 |
| Novo Nordisk | 15 | $226 |
| Lilly USA, LLC | 12 | $217 |
| GSK | 10 | $175 |
| Dexcom, Inc. | 5 | $130 |
| Pfizer | 8 | $128 |
| Amgen(2 entities) | 7 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $105 |
| Exact Sciences | 5 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $74 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| Boehringer Ingelheim | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $45 |
| Nevro Corp. | 2 | $44 |
| Astellas Pharma US Inc | 3 | $41 |
| Corium, LLC | 2 | $39 |
| Radius Health, Inc. | 2 | $38 |
| Nestle Healthcare Nutrition Inc. | 2 | $37 |
| Novartis | 2 | $34 |
| Stryker | 1 | $32 |
| Pacira Pharmaceuticals Incorporated | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Organon | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 2 | $19 |
| Abbott | 1 | $17 |
| Tris Pharma Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$3,745 in reported general payments places this provider in the 75th percentile of 156 sports medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $149,720 |
| JardianceEmpagliflozin | 126 | $149,719 |
| EliquisApixaban | 123 | $104,871 |
| MounjaroTirzepatide | 76 | $81,196 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $43,967 |
| XareltoRivaroxaban | 26 | $32,327 |
| FarxigaDapagliflozin Propanediol | 20 | $30,421 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $28,353 |
| JanuviaSitagliptin Phosphate | 27 | $24,184 |
| VraylarCariprazine Hcl | 11 | $18,522 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 57 | $17,695 |
| EntrestoSacubitril/Valsartan | 11 | $14,948 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $14,466 |
| RybelsusSemaglutide | 12 | $11,358 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 40 | $8,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $226 | $161,077123 claims |
| Boehringer IngelheimJardiance | $54 | $149,719126 claims |
| PfizerEliquis | $128 | $104,871123 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix, Anoro Ellipta | $175 | $90,232198 claims |
| Lilly USA, LLCMounjaro | $217 | $81,19676 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $293 | $58,77465 claims |
| MerckJanuvia | $12 | $24,18427 claims |
| AbbVieVraylar, Synthroid | $1,474 | $21,52877 claims |
| NovartisEntresto | $34 | $14,94811 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $7,747976 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 156 sports medicine providers in Indiana.
Other sports medicine in Sheridan
- Jorge ChahlaMunster$917K
- Sean CallowayGreenwood$130K
- Ryan NixonGreenwood$62K
- Tyler McCarrollCarmel$60K
- Nedal AlkhatibIndianapolis$51K
- Stephen ShivelyGreenfield$51K
- Dale SneadCarmel$45K
- Gregory FoxBloomington$37K
- Gregory WynneNoblesville$36K
- Brian WisselLawrenceburg$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.